2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transfusion, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4562 Beyond the pivotal trials: Outcomes of BCMA-targeted therapies in concurrent AL amyloidosis and multiple myeloma

Jayasree Krishnan, MD, MSPH, Shaniza Haniff, MD MPH2, Wajeeha Aiman, MD3, Silpa Mandava, MD4, Kimberly Newman, MD5, Jens Hillengass, MD, PhD6
1 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
2 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
3 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
4 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
5 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
6 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

Background
Approximately 10–15% of patients (pts) with multiple myeloma (MM) have concurrent immunoglobulin light chain (AL) amyloidosis, a population associated with worse prognosis due to amyloid protein mediated organ damage. B-cell maturation antigen (BCMA)-targeted therapies, including chimeric antigen receptor T-cell (CAR-T) therapies, bispecific antibodies (BsAbs), and antibody-drug conjugates (ADCs), have transformed the treatment landscape for relapsed/refractory MM. However, pts with concurrent AL amyloidosis were systematically excluded from pivotal BCMA-targeted therapy trials, creating a critical evidence gap regarding the safety and efficacy of these agents in this high-risk population. We conducted a real-world propensity score-matched (PSM) analysis to compare outcomes of BCMA-targeted therapy in pts with concurrent AL amyloidosis and MM (AL+MM) versus MM alone.

Methods

Using the TriNetX US Collaborative Network, we identified adults with MM (ICD-10:C90.0x) receiving BCMA-targeted therapy (teclistamab, elranatamab, linvoseltamab, ciltacabtagene autoleucel, idecabtagene vicleucel, or belantamab mafodotin) on or before July 30, 2025. Cohort 1 included patients with concurrent AL amyloidosis (ICD-10:E85.81) and MM; Cohort 2 included MM-alone patients. Index date was first BCMA therapy administration. 1:1 PSM was performed on age, sex, race/ethnicity, hypertension, CKD, heart failure (HF), diabetes, prior autologous transplant, and prior lines of therapy. The primary endpoint was 1-year overall survival (OS). Secondary endpoints included 30-day cytokine release syndrome (CRS) and ICANS; 3-month cytopenias and acute kidney injury (AKI); and 1-year sepsis, hospitalization, hypogammaglobulinemia, arrhythmia, and new HF rates. Exploratory subgroup analyses evaluated CAR-T and BsAb classes separately.

Results
Before matching, 385 AL+MM and 2,467 MM-alone pts were identified. BsAbs were the most common modality in both cohorts (65.5 vs. 58.5%), followed by CAR-T (33.2 vs. 39.5%) and ADC (15.3 vs. 12.4%). After PSM, 381 pts were retained in each cohort with balanced baseline characteristics.

1-year OS was similar between AL+MM and MM-alone cohorts (survival probability 73.8 vs. 76.1%; HR 1.08, 95% CI 0.81-1.44, p=0.60). In unrestricted follow-up, median OS was 1,300 days vs. 1,381 days (HR 1.03, 95% CI 0.81-1.30, p=0.81). At 30 days, no significant difference in CRS (13.2 vs. 12.8%; RR 1.03, p=0.91) or ICANS rates (5.5 vs. 5.7%; RR 0.98, p=0.94) with infrequent grade ≥3 events in both cohorts. At 3 months, rates of thrombocytopenia (19.4 vs. 19.2%; RR 1.01, p=0.96), neutropenia (23 vs. 20%; RR 1.15, p=0.56), and AKI (8.6 vs. 7.4%; RR 1.16, p=0.68) were similar. At 1 year, sepsis (15.1 vs. 13.3%; RR 1.14, p=0.55), new-onset arrhythmia (11.7 vs. 14.0%; RR 0.84, p=0.48), new-onset HF (7.7 vs. 5.6%; RR 1.38, p=0.37), and hospitalization rates were similar. Notably, new-onset hypogammaglobulinemia was higher in the AL+MM cohort (43.7 vs. 35.7%; RR 1.22, 95% CI 0.97-1.54, p=0.087).

In the CAR-T subgroup (143 matched pairs), 1-year OS was identical (85.5 vs. 85.3%; HR 0.95, 95% CI 0.51-1.77, p=0.87) with similar CRS (34.7 vs. 35.6%; RR 0.98, p=0.92) and ICANS (11.2 vs. 12.8%; RR 0.87, p=0.71) rates. New-onset hypogammaglobulinemia at 1-year was similar between groups (48.1 vs. 42.9%; RR 1.12, p=0.50).

In the BsAb subgroup (215 matched pairs), 1-year OS was also similar (68.7 vs. 68.8%; HR 1.01, 95% CI 0.71-1.42, p=0.98). CRS rate was lower overall than in the CAR-T subgroup and comparable between cohorts (9.4 vs. 12.6%; RR 0.75, p=0.42). The hypogammaglobulinemia signal was driven primarily by the BsAb subgroup (45.5 vs. 33.3%; RR 1.37, 95% CI 0.99-1.88, p=0.056).

Conclusions
In this large real-world PSM analysis, concurrent AL amyloidosis did not adversely impact OS, acute immune-mediated toxicity, cytopenias, sepsis, AKI, or arrhythmia in MM pts receiving BCMA-targeted therapy. A trend toward higher rates of new-onset hypogammaglobulinemia was observed in AL+MM pts, driven primarily by BsAbs, consistent with continuous BCMA-targeted plasma cell depletion. These findings support the use of BCMA-targeted therapies in pts with concurrent AL amyloidosis and MM, while highlighting the need for proactive immunoglobulin monitoring and replacement, particularly in pts receiving BsAbs. Prospective studies are warranted to validate these findings and to evaluate organ-specific amyloid responses in this underrepresented population.

Jayasree Krishnan, MD, MSPH: No relevant conflicts of interest to declare.